Allogene PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
---|
Allogene Therapeutics, Inc. (NASDAQ:ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the...
Businesses led by their founders receive significant attention on Wall Street and in academia. For instance, according to research by Bain & Co. published in Harvard Business...
Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7.ZUMA-7 evaluated a one-time...
One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. (NASDAQ:ALLO) . This is because this security in the Medical - Biomedical and...
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Sell | Sell | Neutral | Strong Buy | Neutral |
Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Buy | Sell |
Summary | Strong Sell | Strong Sell | Neutral | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
8.12 | 8.13 | 7.85 | -0.25 | -2.98% | 3.59M | NYSE | |||
4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
31.80 | 31.82 | 30.71 | -0.95 | -2.90% | 4.40M | NYSE | |||
1.1685 | 1.19 | 1.15 | -0.0415 | -3.43% | 1.71M | NYSE | |||
1.075 | 1.09 | 1.05 | -0.0250 | -2.27% | 80.36K | NYSE | |||
45.40 | 45.49 | 44.78 | -0.86 | -1.86% | 1.16M | NYSE | |||
3.525 | 3.55 | 3.47 | -0.075 | -2.08% | 7.76M | NYSE | |||
20.30 | 20.52 | 19.80 | +0.18 | +0.89% | 693.30K | NASDAQ | |||
7.46 | 7.54 | 6.73 | +0.590 | +8.59% | 4.30M | NYSE | |||
14.33 | 15.06 | 13.37 | +1.38 | +10.66% | 77.04M | NASDAQ | |||
49.79 | 49.85 | 47.44 | -1.10 | -2.17% | 1.48M | NYSE | |||
0.78 | 0.79 | 0.776 | -0.010 | -1.27% | 5.42K | NASDAQ | |||
15.24 | 15.30 | 15.00 | +0.02 | +0.13% | 1.57M | OTC Markets | |||
0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
58.50 | 65.70 | 26.90 | +31.47 | +116.43% | 379.46K | NASDAQ |